FDA Sends Warning Letter To Abbott Diabetes Unit

July 20, 2010

Category: | Tags: ,

The Food and Drug Administration (FDA) warned Abbott Laboratories’ (ABT) diabetes unit about manufacturing violations involving the company’s blood-glucose-monitoring systems, according to a report published on NASDAQ.com.

The July 2 letter stemmed from a March inspection of an Abbott Diabetes Care Inc. facility in Alameda, Calif., that makes the FreeStyle glucose-monitoring and the Navigator continuous-monitoring systems. The devices are used by people with diabetes to monitor their blood-glucose, or blood-sugar levels. The letter was posted to FDA’s website Tuesday.

The FDA said the company failed to follow proper quality-control testing and inspection procedures when correcting problems such as scratches found on some FreeStyle Lite monitoring strips.

Add a comment

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>